Synlogic SYBX
Synlogic FY 2022: revenue $1.2M, down 33%; diluted EPS −$0.92
- Form
- 10-K
- Filed
- Period
- Importance
- Notable
- Accession
- 0000950170-23-010428
- Document
- 10-K
Key figures from this report
These are the numbers Synlogic reported for the year ended Dec 31, 2022, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.
- Revenue$1.2M−33% from $1.8M in FY 202110-K income statement, on EDGAR
- Net income−$66.1MAgainst −$60.6M in FY 202110-K income statement, on EDGAR
- Diluted EPS−$0.92Against −$1.09 in FY 202110-K income statement, on EDGAR
- Cash and cash equivalents$15.9M−4% from $16.4M in FY 2021Cash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
- Cash from operations−$56.9MAgainst −$52.2M in FY 202110-K cash flow statement, on EDGAR
Similar companies
Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.
- Matinas BioPharma Holdings MTNB public float $5M, Jun 30, 2025
- China Pharma Holdings CPHI public float $4M, Jun 30, 2025
- Soligenix SNGX public float $5M, Jun 30, 2025
- Target Group CBDY public float $5M, Jun 30, 2025
- Creative Medical Technology Holdings CELZ public float $5M, Jun 30, 2025
